A number of treatment advancements have been made recently in the field of chronic lymphocytic leukemia (CLL), with multiple new drugs approved and even more being explored in clinical trials. In the first-line treatment setting in particular, combinations may be the future of treatment.
Dr. Versha Banerji joined Lymphoma Canada to present the recently published Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia. She aslo discussed relevant research updates regarding front-line treatments for CLL, which were presented at the annual American Society of Hematology (ASH) conference in December 2018.
Speaker Biography:
Dr. Versha Banerji
Dr. Versha Banerji was born and raised in Winnipeg, Manitoba. She completed her undergraduate, medical education and residencies in Internal Medicine at the University of Manitoba. She completed her hematology training at the University of Manitoba and CancerCare Manitoba where she spent much of her clinical and research work with Drs. James Johnston and Spencer Gibson in CLL. She then went on to do a post-doctoral fellowship at the Dana-Farber Cancer Institute and Broad Institute of MIT in Drug Discovery and Target Validation.
Dr. Banerji returned to Manitoba in 2011, where she is part of the CLL Cluster providing clinical care and runs a basic science laboratory testing novel agents, and validating their targets in CLL and other cancer types. She also has a clinical research program evaluating the use of novel agents in the non-clinical trial environment.
A number of treatment advancements have been made recently in the field of chronic lymphocytic leukemia (CLL), with multiple new drugs approved and even more being explored in clinical trials. In the first-line treatment setting in particular, combinations may be the future of treatment.
Dr. Versha Banerji joined Lymphoma Canada to present the recently published Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia. She aslo discussed relevant research updates regarding front-line treatments for CLL, which were presented at the annual American Society of Hematology (ASH) conference in December 2018.
Speaker Biography:
Dr. Versha Banerji
Dr. Versha Banerji was born and raised in Winnipeg, Manitoba. She completed her undergraduate, medical education and residencies in Internal Medicine at the University of Manitoba. She completed her hematology training at the University of Manitoba and CancerCare Manitoba where she spent much of her clinical and research work with Drs. James Johnston and Spencer Gibson in CLL. She then went on to do a post-doctoral fellowship at the Dana-Farber Cancer Institute and Broad Institute of MIT in Drug Discovery and Target Validation.
Dr. Banerji returned to Manitoba in 2011, where she is part of the CLL Cluster providing clinical care and runs a basic science laboratory testing novel agents, and validating their targets in CLL and other cancer types. She also has a clinical research program evaluating the use of novel agents in the non-clinical trial environment.
